The long-term goal of this work is to elucidate the mechanisms underlying the dyskinesias which develop in Parkinson's disease in response to chronic L-dopa treatment, and to identify therapeutic means to ameliorate or prevent them. The pathogenesis of L-dopa-induced dyskinesias remains poorly understood; however, since a combination of striatal dopaminergic denervation and chronic drug administration are both required for its induction, it is generally thought that a complex series of changes in basal ganglia circuitry is involved. In this proposal, we will test specific alterations in both pre- and postsynaptic neuronal function in distinct regions of the basal ganglia thought to be involved in dopa-dyskinesias and correlate observed changes with the onset and/or occurrence of dyskinesias. To approach this we will test the hypotheses (1) that, with a decline in the number of surviving dopaminergic neurons, there is a decreased capacity to buffer changes in the availability of L-dopa and/or dopamine, (2) that specific dopamine receptor subtype modifications in the striatopallidal complex and other brain areas are linked to the onset of L-dopa-induced dyskinesias and (3) that glutamate receptors are upregulated with the occurrence of dyskinesia as studies have shown that glutamate receptor blockers suppress dyskinesias. We will use a well-characterized model, developed in our laboratory, of dopa-dyskinesias in squirrel monkeys rendered parkinsonian by systemic injection of the selective dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Since the observed dyskinesias are essentially identical to those which occur in parkinsonian patients and in humans with MPTP-induced parkinsonism, we have an excellent experimental paradigm with which to investigate the current hypotheses on the pathophysiology of dopa-dyskinesias. These studies will enhance our understanding of the pathophysiology of dopa-dyskinesias, and could lead to new strategies for their prevention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS034886-01A2
Application #
2410363
Study Section
Neurology A Study Section (NEUA)
Program Officer
Oliver, Eugene J
Project Start
1997-12-01
Project End
2000-11-30
Budget Start
1997-12-01
Budget End
1998-11-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Parkinson's Institute
Department
Type
DUNS #
614259935
City
Sunnyvale
State
CA
Country
United States
Zip Code
94085
Quik, Maryka; O'Leary, Kathryn; Tanner, Caroline M (2008) Nicotine and Parkinson's disease: implications for therapy. Mov Disord 23:1641-52
Cox, Heather; Togasaki, Daniel M; Chen, Li et al. (2007) The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol 205:101-7
Togasaki, Daniel M; Protell, Peter; Tan, Louis C S et al. (2005) Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology 48:398-405
Togasaki, Daniel M; Hsu, Albert; Samant, Meghana et al. (2005) The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods 145:159-66
Chen, L; Togasaki, D M; Langston, J W et al. (2005) Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience 132:409-20
Hsu, Albert; Togasaki, Daniel M; Bezard, Erwan et al. (2004) Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther 311:770-7
Quik, M; Police, S; Langston, J W et al. (2002) Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 113:213-20
Tan, Louis C; Protell, Peter H; Langston, J William et al. (2002) The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord 17:902-9
Petzinger, G M; Quik, M; Ivashina, E et al. (2001) Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate. Mov Disord 16:202-7
Togasaki, D M; Tan, L; Protell, P et al. (2001) Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 50:254-7

Showing the most recent 10 out of 15 publications